Arcturus Therapeutics (NASDAQ:ARCT) issued its earnings results on Monday. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by ($0.15), MarketWatch Earnings reports. The company had revenue of $4.35 million during the quarter, compared to the consensus estimate of $3.47 million.
Shares of Arcturus Therapeutics stock traded up $0.04 on Tuesday, reaching $5.84. The company had a trading volume of 9 shares, compared to its average volume of 47,667. The stock has a market cap of $62.42 million, a price-to-earnings ratio of -2.70 and a beta of 2.19. The company has a debt-to-equity ratio of 0.73, a quick ratio of 3.33 and a current ratio of 3.33. Arcturus Therapeutics has a 1 year low of $4.11 and a 1 year high of $10.00.
A number of analysts have issued reports on ARCT shares. Laidlaw started coverage on Arcturus Therapeutics in a research note on Tuesday, February 19th. They issued a “buy” rating on the stock. Zacks Investment Research raised Arcturus Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, March 18th. HC Wainwright began coverage on Arcturus Therapeutics in a research note on Friday, April 5th. They issued a “buy” rating and a $15.00 price objective on the stock. Chardan Capital reiterated a “buy” rating and issued a $18.00 target price on shares of Arcturus Therapeutics in a report on Tuesday, March 19th. Finally, ValuEngine upgraded Arcturus Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, March 30th. Eight research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $13.83.
Arcturus Therapeutics Company Profile
Arcturus Therapeutics Ltd., an RNA medicines company, focuses on treatment of liver and respiratory diseases. The company's pipeline of RNA therapeutics include programs pursuing rare diseases, hepatitis B, non-alcoholic steatohepatitis, cystic fibrosis, and vaccines. The company owns LUNAR lipid-mediated delivery and Unlocked Nucleomonomer Agent (UNA) technology, including UNA Oligomers, which are covered by its patent portfolio, including 152 patents and patent applications issued in the United States, Europe, Japan, China, and internationally.
Featured Article: Why do commodities matter?
Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.